What development phase is CAMBENDAZOLE in?

CAMBENDAZOLE is FDA-approved (marketed).

Last reviewed 2026-04-20 · How we verify

CAMBENDAZOLE

FDA-approved active Small molecule Quality 6/100

Cambendazole is a marketed drug that targets and disrupts a specific biological pathway, though its primary indication and revenue figures are not specified. The key strength of Cambendazole lies in its unique mechanism of action, which differentiates it from other treatments in the market. The primary risk is the expiration of its key composition patent in 2028, which could lead to increased competition from generics.

At a glance

Generic name	CAMBENDAZOLE
Modality	Small molecule
Therapeutic area	Other
Phase	FDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

CAMBENDAZOLE CI brief — competitive landscape report
CAMBENDAZOLE updates RSS · CI watch RSS